FDA
-
-
-
-
-
-
-
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
-
-
-
-
-
-
-
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
-
-
-
-
-
-
-
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

